acute exacerbation of idiopathic pulmonary fibrosis
Conditions
Interventions
The patients diagnosed as AE-IPF are treated with m-PSL pulse therapy and intravenous recombinant human soluble thrombomodulin (rhTM) within 24 hrs after the diagnosis.
Sponsors
Toho university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients admitted to Toho Univercity Sakura hospital and diagnosed AE-IPF based on the ATS/ERS/JRS guidelines
Exclusion criteria
Exclusion criteria: 1)A person having an infection of apparent activity 2)Those who have apparent congestive heart failure. 3) Those who have apneumothorax 4) Those who have athma 5) Those who have deep vein thrombosis to be treated. 6) Who has the possibility of pulmonary arterial thromboembolism 7) A person who has circulatory failure, renal failure, liver failure 8) Those who have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding 9)A person with a history of hypersensitivity to components of the thrombomodulin 10) Women who may be pregnant or are pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of P/F ratio before and after 7days of administration of recombinant human soluble thrombomodulin. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.D-dimer value at the 1,4,8,15,29 hospital days. 2.P/F ratio at the 1,8,15,29 hospital days. 3.the survival rate at the 29 hospital days | — |
Countries
Japan
Contacts
Public ContactYasuo Matsuzawa
Toho university Division of Pneumology
Outcome results
None listed